Format

Send to

Choose Destination
Endocrinol Metab (Seoul). 2020 Mar;35(1):177-187. doi: 10.3803/EnM.2020.35.1.177.

Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas.

Author information

1
Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea.
2
Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.
3
Endocrinology Research, Ipsen Bioscience Inc., Cambridge, MA, USA.
4
Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea. cr079@yuhs.ac.
5
Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea. ejlee423@yuhs.ac.
#
Contributed equally

Abstract

BACKGROUND:

Acromegaly is a rare disease primarily caused by growth hormone (GH)-secreting pituitary adenomas, and its treatment is costly. Moreover, some patients are unresponsive to treatment. Hence, there are increasing efforts to develop new drugs with improved effectiveness for this disease. BIM23B065 is a novel chimeric molecule that acts on both somatostatin and dopamine receptors. This study aimed to investigate the effects of BIM23B065 compared with those of a somatostatin receptor analog and a dopamine agonist.

METHODS:

The effects of BIM23B065 on the proliferation, GH and insulin-like growth factor-1 (IGF-1) levels, and extracellular signal-regulated kinase (ERK) 1/2 and cyclic AMP response element binding (CREB) phosphorylation of GH3 cells were investigated with MTS assay, enzyme-linked immunosorbent assay, and Western blotting, respectively. The dosage and treatment duration of BIM23B065 were tested in animal models of GH-secreting pituitary adenoma. The effect of BIM23B065 (3 mg/kg/day) on changes in IGF-1 levels before and after treatment was further investigated.

RESULTS:

In vitro, BIM23B065 treatment decreased GH release in the culture media and downregulated ERK 1/2 and CREB phosphorylation to 22% and 26%, respectively. In vivo, IGF-1 expression decreased to 50 % after 4 weeks of treatment with BIM23B065 using an osmotic pump implant. Moreover, magnetic resonance imaging results showed that the tumor size decreased significantly following treatment with BIM23B065 for 4 weeks.

CONCLUSION:

The novel chimeric molecule was effective in decreasing IGF-1 and GH levels and may serve as an effective therapeutic agent for acromegaly.

KEYWORDS:

Acromegaly; Growth hormone; Insulin-like growth factor I; Pituitary neoplasms; Therapeutics

Supplemental Content

Full text links

Icon for Korean Endocrine Society Icon for PubMed Central
Loading ...
Support Center